These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6191064)

  • 1. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A; Comar OB; Taccone W; Cicalese V
    Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM; Lynch JH
    J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I; Budavári I; Kisbenedek L; Balogh F
    Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

  • 12. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S; Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract]   [Full Text] [Related]  

  • 13. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE; Pachas WN; Pinals RS; Krant MJ
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract]   [Full Text] [Related]  

  • 14. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC; Fellows GJ
    Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
    Ikeda I; Miura T; Kondo I
    Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D; Adalar N; Güvençli S; Simşek F
    Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
    Heller W; Harzmann R; Bichler KH; Schmidt K
    Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF; Taft EG; Olson KB; Gates S; Beebe RT
    Arch Intern Med; 1966 Dec; 118(6):565-71. PubMed ID: 5925444
    [No Abstract]   [Full Text] [Related]  

  • 20. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.